Sign in

FluoRok

Series A · €26.64M · November 2026 · Biotech & pharma · Europe

What it sells

FluoRok develops fluorochemical manufacturing technology that bypasses hazardous hydrogen fluoride, starting with inorganic fluorides (NaF, KF, LiF), battery materials and waste fluoropolymer valorisation.

Funding history and coverage

Round dateStageAmountInvestorsSource
2026-11-05—€26.64M—news.google.com
2026-11-05Series A$30M—news.google.com
2026-11-05Series A$30M—news.google.com
2026-11-05Series A$30M—news.google.com
2026-11-05—€26.64M—eu-startups.com

Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-11-10.

More startups in Biotech & pharma

  1. Kardi Ai

    Kardi Ai is a non-invasive, reusable single-lead ECG medical device for adults that records and analyses the heart's electrical activity, for home or clinical use, detecting…

    Series A · €5.3M · 2026-11-11Biotech & pharmaEurope

  2. Switchpoint Bio

    Switchpoint Bio combines blood-based epigenomics (DNA methylation) and AI to produce decision-grade evidence for drug development: biomarker discovery, patient stratification and…

    $5.3M · 2026-11-11Biotech & pharmaEurope

  3. SRTD Biotech

    Cell-selective mRNA therapeutics: seRNA constructs are delivered inactive and switch on only when they detect a disease-specific RNA inside the target cell, found by an AI…

    Seed · €31.5M · 2026-11-10Biotech & pharmaEurope

  4. Lucidome Bio

    Lucidome Bio is developing a vaccine that triggers antibodies against methanogens in the rumen to cut methane emissions from cattle and other ruminant livestock, including…

    $9M · 2026-11-10Biotech & pharmaAsia

  5. Efferon

    Efferon makes CE-marked multimodal hemoadsorption devices (Efferon LPS for adults, Efferon NEO for children) that remove endotoxin and cytokines from the blood to treat sepsis…

    Seed · €4.3M · 2026-11-10Biotech & pharmaEurope

  6. Oyster Therapeutics

    Develops targeted protein degrader therapeutics using its SELFTAC platform, where two small molecules cross biological barriers and self-assemble into a full degrader. First…

    Series A-2 · $60M · 2026-11-10Biotech & pharmaOther regions

All startups in this market →